Bruce E. Sands, MD
Assistant Professor of Medicine
Harvard Medical School
| Address: | Massachusetts General Hospital MGH Digestive Health Center 100 Charles River Plaza, 9th Floor Boston, MA 02114 |
| Patient Appointments: | (617) 724-6005 |
| Academic Phone: | (617) 724-7571 |
| Fax: | (617) 726-3080 |
| E-Mail: | bsands@partners.org |
| Clinical Background: | |
| MD Degree: | Boston University School of Medicine, 1987 |
| Residency: | Hospital of the University of Pennsylvania, 1990 |
| Fellowship: | Massachusetts General Hospital, 1994 |
| Other: | Masters of Science, Epidemiology Harvard School of Public Health, 2001 |
| Board Certifications: | Internal Medicine, 1990, 1999 Gastroenterology, 1993, 2002 |
| Clinical Interests: | General Gastroenterology Inflammatory Bowel Disease |
Research Interests:
Clinical trials of novel therapeutic agents and modalities for Crohn's disease and ulcerative colitis; genotype-phenotype correlations in IBD; validation of disease/treatment outcomes in IBD; prognostic factors in the clinical course of Crohn's disease; pharmacoepidemiology.
Recent Publications:
- Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7(2):83-8.
- Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US, . Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16(3):399-406
- Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003; 17(11):1355-64.
- Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, Klibanski A. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab 2003; 88(11):5468-72
- Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98(12):2712-8.
- Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350(9):876-85
- Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126(6):1518-32.
- Forcione DG. Rosen MJ. Kisiel JB. Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 53(8):1117-22, 2004 Aug.
